SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001493152-22-012893
Filing Date
2022-05-12
Accepted
2022-05-11 19:54:49
Documents
14
Period of Report
2022-05-11
Items
Item 7.01: Regulation FD Disclosure
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 form8-k.htm   iXBRL 8-K 61416
2 ex99-1.htm EX-99.1 35459
3 ex99-1_001.jpg GRAPHIC 7167
  Complete submission text file 0001493152-22-012893.txt   293101

Data Files

Seq Description Document Type Size
4 INLINE XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT lctx-20220511.xsd EX-101.SCH 2968
5 INLINE XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT lctx-20220511_lab.xml EX-101.LAB 34240
6 INLINE XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT lctx-20220511_pre.xml EX-101.PRE 22365
8 EXTRACTED XBRL INSTANCE DOCUMENT form8-k_htm.xml XML 3608
Mailing Address 2173 SALK AVENUE SUITE 200 CARLSBAD CA 92008
Business Address 2173 SALK AVENUE SUITE 200 CARLSBAD CA 92008 5105213390
Lineage Cell Therapeutics, Inc. (Filer) CIK: 0000876343 (see all company filings)

IRS No.: 943127919 | State of Incorp.: CA | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-12830 | Film No.: 22915299
SIC: 2836 Biological Products, (No Diagnostic Substances)